Pay in 4 interest-free payments of $7.42 Learn more
Ships within 48 hours · Estimated delivery Aug 19 - Aug 24
Delays can arise from clinical trial results, regulatory review, or production issues
The rationale for the first engineered GLP-1/GCGR co-agonist [114] originated from the observation that chronic administration of a water-soluble form of glucagon not only decreased body weight in mice with DIO, but also improved glucose tolerance with an efficacy similar to that obtained with exendin-4 [70]
For a broader overview of fat loss compounds, see our best peptides for weight loss guide
Average weight loss of 22.5% at the 15mg dose
Early phase 2 clinical trial data also suggest a possible contribution to increased energy expenditure, though this effect has not yet been definitively confirmed as a major contributor to weight loss in humans and remains an area of ongoing investigation
As this article has outlined, the honest answers are troubling
